Bioengineered E. coli bacteria can now produce a group of compounds with anticancer, anti-HIV, antidiabetic and anti-inflammatory activities. The Kobe University achievement is the result of a rational design strategy that yields a platform for the industrial production of drug candidates.

Plants produce many substances with promising pharmacological activities. For example, Rhododendron species produce a class of compounds, called orsellinic acid-derived meroterpenoids, with remarkable anticancer, anti-HIV, antidiabetic and anti-inflammatory activities.

A new study published by Mayo Clinic researchers suggests that ovarian cancer cells quickly activate a survival response after PARP inhibitor treatment, and blocking this early response may make this class of drugs work better.

PARP inhibitors are a common treatment for ovarian cancer and can be especially effective in cancers with impaired DNA repair.

Indiana University School of Medicine scientists have identified a promising drug target for Alzheimer's disease. The team found that removing an enzyme from neurons in the brain substantially reduces amyloid plaques - a hallmark characteristic of the disease - and may provide further resilience against disease progression.

Hepatocellular carcinoma (HCC) is a leading cause of cancer death worldwide, often driven by abnormal lipid metabolism and excessive blood vessel growth. In a new study, researchers from Fudan University and Wenzhou Medical University have uncovered how disulfiram - a long-used anti-alcoholism medication - exerts potent anti-tumor effects in liver cancer.

Cardiovascular diseases (CVDs) remain a leading cause of global morbidity and mortality, with significant residual risk unexplained by traditional factors. The discovery of novel therapeutic targets or the repurposing of existing drug targets could improve the prevention and treatment for different CVDs. However, previous studies have encountered different analytic challenges, such as failing to cover the whole spectrum of CVDs,

Genetically modified immune cells can offer precious additional time to patients with advanced multiple myeloma. However, these therapies lose their impact as the molecules on cancer cells that immune cells recognize gradually vanish. Researchers at the Technical University of Munich (TUM) have now identified one of the molecular mechanisms behind this process. In an initial study they succeeded in blocking it using an existing cancer drug.

Patients who use semaglutide for weight loss, like Ozempic, are more likely to continue the medication if they perceive it as effective, even when facing unpleasant side effects, according to Rutgers Health researchers.

Their study, published in Journal of Medical Internet Research, found perceived effectiveness - reductions in weight, appetite or food cravings - was the strongest predictor of satisfaction and intention to continue treatment, regardless of side effects.

Pfizer Inc. (NYSE: PFE) announced the launch of its program on TrumpRx, making innovative medicines more affordable and accessible to millions of Americans. The program provides Americans a wide range of more than 30 medicines at a significant discount off list prices.

Whether a smartphone battery lasts longer or a new drug can be developed to treat incurable diseases depends on how stably the atoms constituting the material are bonded. The core of 'molecular design' lies in finding how to arrange these countless atoms to form the most stable molecule. Until now, this process has been as difficult as finding the lowest valley in a massive mountain range, requiring immense time and costs.

Cardiovascular disease results in around 20 million deaths worldwide and causes around a quarter of all deaths in the UK. Statins are highly effective drugs that lower LDL ("bad") cholesterol levels and have been repeatedly proven to reduce the risk of cardiovascular disease. However, there have been concerns about possible side effects.

Fecal microbiota transplants (FMT), can dramatically improve cancer treatment, suggest two groundbreaking studies published in the prestigious Nature Medicine journal. The first study shows that the toxic side effects of drugs to treat kidney cancer could be eliminated with FMT. The second study suggests FMT is effective in improving the response to immunotherapy in patients with lung cancer and melanoma.

On January 29, 2026, Sanofi announced its intention to execute a share buyback program in 2026 of €1 billion.

On February 2, 2026, Sanofi entered a mandate with an investment service provider for this program. Under the terms of the mandate, Sanofi will repurchase its own shares for a total consideration of up to €1 billion, between February 3, 2026, and December 31, 2026, at the latest(1).

A team of researchers at VCU Massey Comprehensive Cancer Center discovered an innovative way to use a drug already approved in treating irregular heartbeat to selectively target specific functions of enzymes in lymphoma, effectively killing cancer cells and reducing tumor growth with little to no toxicity. Recent findings published in Pharmacological Research set the groundwork for how this strategy could help transform the future of precision medicine in cancer.

Although DNA is tightly packed and protected within the cell nucleus, it is constantly threatened by damage from normal metabolic processes or external stressors such as radiation or chemical substances. To counteract this, cells rely on an elaborate network of repair mechanisms. When these systems fail, DNA damage can accumulate, impair cellular function, and contribute to cancer, aging, and degenerative diseases.

AstraZeneca today begins trading its ordinary shares on the New York Stock Exchange (NYSE) for the first time, enabling more US investors to participate in the Company’s strong growth. With this change the trading of AstraZeneca ordinary shares is now aligned across the NYSE, the London Stock Exchange (LSE) and Nasdaq Stockholm (STO) under a harmonised listing structure.

Multiple randomized clinical trials and electronic health record studies now show that metformin, a widely used and well-established medication, significantly reduces the risk of developing Long COVID when taken during or shortly after acute infection with SARS-CoV-2. The findings were published in Clinical Infectious Diseases.

In the paper, the University of Minnesota Medical School research team provides information about metformin and summarizes several studies in low, standard and high risk populations

A short-term oat-based diet appears to be surprisingly effective at reducing the cholesterol level. This is indicated by a trial by the University of Bonn, which has been published in the journal Nature Communications. The participants suffered from a metabolic syndrome - a combination of high body weight, high blood pressure, and elevated blood glucose and blood lipid levels. They consumed a calorie-reduced diet, consisting almost exclusively of oatmeal, for two days.

Chemotherapy commonly damages the intestinal lining, a well-known side effect. But this injury does not remain confined to the gut. It reshapes nutrient availability for intestinal bacteria, forcing the microbiota to adapt.

The researchers report that chemotherapy-induced damage to the intestinal lining alters nutrient availability for gut bacteria, reshaping the microbiota and increasing the production of

Abbott (NYSE: ABT) announced that its board of directors has increased the company's quarterly common dividend to 63 cents per share, an increase of 6.8%. The company's quarterly dividend payout has increased more than 70% since 2020.

This marks Abbott's 54th consecutive year of dividend growth and is the 408th consecutive quarterly dividend to be paid by Abbott since 1924.

A newly published perspective article in Nature Nanotechnology details groundbreaking nanoparticle technology to eliminate harmful, disease-causing proteins in the body. The technology marks a transformative leap in the potential to drug "undruggable" proteins, to treat diseases such as dementia and brain cancer.

The research was led by Chair Professor in Nanomedicine Bingyang Shi from the University of Technology Sydney (UTS), together with international collaborators Professor Kam Leong from Columbia University, and Professor Meng Zheng from Henan University.